Our findings potentiate the therapeutic concept that inhibition of ET-1 signaling with dual ETAR/ETBR antagonist blockade might selectively target tumor-supporting CAFs that impact matrisome components and ECM organization, key features of tumor initiation and progression. This evidence concerns the gene EDNRA and neoplasm.